Lawmakers in Springfield are seeking to put together a board to lookout for price gouging.
Peter Sawicki, M.D., Ph.D., director of Germany's Institute for Quality and Efficiency in Health Care, reviews how his agency aims to inform policy, as well as patients and doctors.
Chair of the Australian Pharmaceutical Benefits Advisory Committee (PBAC), looks at how comparative effectiveness research helps give Australians "access to drugs that work at a cost they as individuals and we as a country can afford."
Sir Michael Rawlins, chairman of the U.K.'s Institute for Health and Clinical Excellence (NICE), observes that NICE has increased the new drugs available to patients and patients are getting a lot of benefit from it.
Chair of the French National Authority for Health (HAS), outlines the four principles of comparative effectiveness research in France, beginning with principle that comparative effectiveness research is independent of decision makers and payers.